论文部分内容阅读
新修订药品GMP的岀台,将使一批中小药企淘汰岀局。而一些具有预见性眼光的企业已付诸行动,抢占发展先机。2011年10月中旬,山西省为制药企业实施《药品生产质量管理规范(2010年修订)》(简称“新修订药品GMP”)排定最后时限:118家药品生产企业必须在5年内达到相关认证要求,否则将面临停产。新修订药品GMP的出台,对山西省制药企业将带来巨大冲击,一批中小药企有可能被淘汰出局。而一些具有预见性眼光的企业已付诸行动,抢占发展先机。
The new amendments to the pharmaceutical GMP will enable a group of small and medium-sized pharmaceutical companies to eliminate the bureaucratic situation. Some companies with predictable visions have already taken actions to seize development opportunities. In mid-October 2011, Shanxi Province implemented a final time limit for pharmaceutical companies to implement the “Quality Control Regulations for Pharmaceutical Production (Revised in 2010)” (abbreviated as “The Newly Revised Drug GMP”): 118 drug manufacturers must achieve within 5 years. Related certification requirements, otherwise they will face production suspension. The promulgation of the newly revised pharmaceutical GMP will have a huge impact on pharmaceutical companies in Shanxi Province, and a group of small and medium-sized pharmaceutical companies may be eliminated. Some companies with predictable visions have already taken actions to seize development opportunities.